Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.

Julie Vanderpoel Andrea L Stevens Bruno EmondMarie-Hélène LafeuilleAnnalise HiltsPatrick LefebvreLaura Morrison

Published in: Journal of medical economics (2022)

NGS was associated with the fastest time to appropriate targeted therapy initiation and lowest total cost of testing compared to PCR testing strategies for newly diagnosed patients with mNSCLC.

Keyphrases

newly diagnosed
squamous cell carcinoma
small cell lung cancer
copy number
gene expression
dna methylation